Discovering that my lipoprotein(a) levels were higher than recommended was a shock, especially considering my commitment to a healthy lifestyle. This discovery unveiled a startling truth: testing for lipoprotein(a) and the best treatments for managing levels are not readily accessible in the UK. This must change.

Lipoprotein(a) is a genetic risk factor closely linked to cardiovascular diseases, which can lead to heart attacks and strokes. Despite maintaining a balanced diet, regular exercise, and overall healthy practices, individuals like me remain at risk due to limited testing and treatment options in our health system. This gap in our healthcare approach leaves many unaware of their condition until it's too late.

Promising new treatments are on the horizon, with some nearing approval stages. These innovative solutions could significantly mitigate the risks posed by elevated lipoprotein(a) levels. However, without proper accessibility and testing options, countless individuals might miss these life-saving advancements.

The UK's healthcare system should prioritize wider availability of testing for lipoprotein(a) levels and ensure timely access to these emerging treatments. Doing so could prevent premature cardiovascular diseases, saving lives and reducing long-term healthcare costs significantly.

It's time for our healthcare leaders to acknowledge the importance of equitable access to lipoprotein(a) testing and treatments. The inclusion of such measures will strengthen the health framework and offer hope to those living with elevated lipoprotein(a) levels.

Please sign this petition to urge policymakers and healthcare providers to increase testing availability and introduce new treatments for lipoprotein(a) in the UK. Together, we can enhance our healthcare system and safeguard the heart health of our communities.